This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Galectin-3	<i>In vitro</i> and mouse studies suggest that inhibiting galectin-3 could be antiangiogenic and help treat cancer. In cultured endothelial cells, galectin-3 inhibitors or small interfering RNA against the target prevented VEGF- or fibroblast growth factor (FGF)-induced cell migration and capillary formation compared with no treatment or nontargeted siRNA. In <i>galectin-3</i> ^{-/-} mice, Vegf- or Fgf-induced neovascularization of the cornea was impaired compared with that in wild-type mice. Next steps could include preclinical studies in disease models.	Patent and licensing status unavailable	Markowska, A.I. <i>et al. J. Exp. Med.</i> ; published online Aug. 16, 2010; doi:10.1084/jem.20090121 Contact: Noorjahan Panjwani, Tufts University School of Medicine, Boston, Mass. e-mail: noorjahan.panjwani@tufts.edu
<i>SciBX</i> 3(35); doi:10.1038/scibx.2010.1062 Published online Sept. 9, 2010				